AR110498A1 - DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 - Google Patents
DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5Info
- Publication number
- AR110498A1 AR110498A1 ARP170103429A ARP170103429A AR110498A1 AR 110498 A1 AR110498 A1 AR 110498A1 AR P170103429 A ARP170103429 A AR P170103429A AR P170103429 A ARP170103429 A AR P170103429A AR 110498 A1 AR110498 A1 AR 110498A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- iii
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composiciones que incluye los compuestos y uso de los compuestos en el tratamiento de la enfermedad de Alzheimer. Reivindicación 1: Compuestos de fórmula (1) en donde X se selecciona de entre i) N, y ii) CH; Y se selecciona de entre i) N, y ii) CR¹⁰; Z se selecciona de entre i) N, y ii) CR¹¹; R¹ se selecciona de entre i) alquilo C₁₋₆, ii) halo-alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) halo-alcoxi C₁₋₆, v) hidroxi-alquilo C₁₋₆, vi) cicloalquilo C₃₋₈, vii) halógeno, y viii) amino sustituido en el átomo de nitrógeno con uno o dos sustituyentes seleccionados independientemente de entre a) H, b) alquilo C₁₋₆, y c) cicloalquilo C₃₋₈; R² se selecciona de entre i) H, y ii) halógeno; R³ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) cicloalquilo C₃₋₈, iv) hidroxi-alquilo C₁₋₆, y v) halo-alquilo C₁₋₆; R⁴ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; R⁵ es H; R⁶ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) cicloalquilo C₃₋₈ sustituido con R⁷, R⁸ y R⁹, iv) cicloalquil C₃₋₈-alquilo C₁₋₆ sustituido con R⁷, R⁸ y R⁹, v) alquilsulfonil C₁₋₆-alquilo C₁₋₆, vi) ciano-alquilo C₁₋₆, vii) hidroxi-alquilo C₁₋₆, viii) dihidroxi-alquilo C₁₋₆, ix) halo-alquilo C₁₋₆, x) heterocicloalquilo sustituido con R⁷, R⁸ y R⁹, y xi) heterocicloalquil-alquilo C₁₋₆ sustituido con R⁷, R⁸ y R⁹; R⁷, R⁸ y R⁹ se seleccionan independientemente de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) alcoxialquilo C₁₋₆, v) alcoxicarbonilo C₁₋₆, vi) ciano, vii) cicloalcoxi C₃₋₈, viii) cicloalquilo C₃₋₈, ix) halo-alcoxi C₁₋₆, x) halo-alquilo C₁₋₆, xi) halógeno, xii) hidroxi, xiii) hidroxi-alquilo C₁₋₆, y xiv) oxo; R¹⁰ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; R¹¹ se selecciona de entre i) H, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) cicloalquilo C₃₋₈, y v) halógeno; o R⁵ y R¹⁰ forman juntos -(CH₂)ₙ-; o R⁵ y R¹¹ forman juntos -(CH₂)ₙ-; o R⁵ y R⁶ junto con el átomo de nitrógeno al que están unidos forman un heterocicloalquilo sustituido con R⁷, R⁸ y R⁹; n se selecciona de entre 1 y 2; o sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110498A1 true AR110498A1 (es) | 2019-04-03 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103429A AR110498A1 (es) | 2016-12-08 | 2017-12-07 | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (es) |
| EP (1) | EP3551627B1 (es) |
| JP (1) | JP7084405B2 (es) |
| KR (1) | KR102564643B1 (es) |
| CN (2) | CN109923113B (es) |
| AR (1) | AR110498A1 (es) |
| AU (1) | AU2017373734B2 (es) |
| BR (1) | BR112019006571A2 (es) |
| CA (1) | CA3040024A1 (es) |
| CL (1) | CL2019001458A1 (es) |
| CO (1) | CO2019002692A2 (es) |
| CR (1) | CR20190268A (es) |
| DK (1) | DK3551627T3 (es) |
| ES (1) | ES2910110T3 (es) |
| HR (1) | HRP20220468T1 (es) |
| HU (1) | HUE058355T2 (es) |
| IL (1) | IL267054B (es) |
| LT (1) | LT3551627T (es) |
| MA (1) | MA48594B1 (es) |
| MX (1) | MX388725B (es) |
| MY (1) | MY200641A (es) |
| PE (1) | PE20191156A1 (es) |
| PH (1) | PH12019500664B1 (es) |
| PL (1) | PL3551627T3 (es) |
| PT (1) | PT3551627T (es) |
| RS (1) | RS63106B1 (es) |
| SI (1) | SI3551627T1 (es) |
| TW (1) | TWI642666B (es) |
| UA (1) | UA125524C2 (es) |
| WO (1) | WO2018104419A1 (es) |
| ZA (1) | ZA201902225B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388725B (es) | 2016-12-08 | 2025-03-11 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5. |
| JP7478676B2 (ja) | 2018-06-13 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | Ｇａｂａ ａ ａｌｐｈａ５ ｐａｍとしての新規イソオキサゾリルエーテル誘導体 |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| WO2021191837A1 (en) * | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| WO2022234271A1 (en) | 2021-05-05 | 2022-11-10 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| AU2023288711A1 (en) | 2022-06-20 | 2024-11-07 | F. Hoffmann-La Roche Ag | Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| AU2023370005A1 (en) | 2022-10-25 | 2025-04-10 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
| CN121001709A (zh) | 2023-04-24 | 2025-11-21 | 豪夫迈·罗氏有限公司 | 包含6-((5-甲基-3-(6-甲基吡啶-3-基)异噁唑-4-基)甲氧基)-n-(四氢吡喃-4-基)哒嗪-3-甲酰胺的片剂 |
| WO2024251133A1 (zh) * | 2023-06-05 | 2024-12-12 | 武汉人福创新药物研发中心有限公司 | 作为α5-GABAA受体调节剂的杂环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100015648A (ko) * | 2007-04-18 | 2010-02-12 | 아스트라제네카 아베 | 양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물 |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| MX2010005717A (es) * | 2007-12-04 | 2010-06-02 | Hoffmann La Roche | Derivados de isoxazolo-piridina. |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| AU2010244553A1 (en) | 2009-05-05 | 2011-12-01 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| ES2711973T3 (es) * | 2010-11-05 | 2019-05-08 | Hoffmann La Roche | Uso de compuestos farmacéuticos activos para el tratamiento de afecciones del sistema nervioso central |
| ES2763332T3 (es) * | 2011-09-15 | 2020-05-28 | Hoffmann La Roche | Nuevos derivados de dihidroquinolin-2-ona |
| JP2018523679A (ja) | 2015-08-17 | 2018-08-23 | ルピン・リミテッド | Ｐａｒｐ阻害剤としてのヘテロアリール誘導体 |
| DK3399984T3 (da) | 2016-01-08 | 2023-11-13 | Arcus Biosciences Inc | Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf |
| DK3399978T3 (da) | 2016-01-08 | 2020-11-16 | Celgene Corp | Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf |
| MX388725B (es) | 2016-12-08 | 2025-03-11 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5. |
-
2017
- 2017-12-07 MX MX2019006696A patent/MX388725B/es unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
- 2017-12-07 BR BR112019006571-7A patent/BR112019006571A2/pt active Search and Examination
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 PH PH1/2019/500664A patent/PH12019500664B1/en unknown
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active Active
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/en active Active
- 2017-12-07 MY MYPI2019001529A patent/MY200641A/en unknown
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/en not_active Ceased
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es active IP Right Grant
- 2017-12-07 CA CA3040024A patent/CA3040024A1/en active Pending
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR116913A1 (es) | Inhibidores de apol1 y sus métodos de uso | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR119000A1 (es) | Aril amidinas fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |